1 / 25

Ory Rouvio, Tsila Zuckerman, Izhar Hardan, Moshe Yeshurun, Simcha Samuel, and Itai Levi

Stem Cell Mobilization Using the Combination of Plerixafor and G-CSF in Patients Previously Failed G-CSF Mobilization Alone: Preliminary Experience in Israel. Ory Rouvio, Tsila Zuckerman, Izhar Hardan, Moshe Yeshurun, Simcha Samuel, and Itai Levi ISH Spring 2009 meeting.

walker
Télécharger la présentation

Ory Rouvio, Tsila Zuckerman, Izhar Hardan, Moshe Yeshurun, Simcha Samuel, and Itai Levi

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Stem Cell Mobilization Using the Combination of Plerixafor and G-CSF in Patients Previously Failed G-CSF Mobilization Alone: Preliminary Experience in Israel. Ory Rouvio, Tsila Zuckerman, Izhar Hardan, Moshe Yeshurun, Simcha Samuel, and Itai Levi ISH Spring 2009 meeting

  2. Factors associated with poor mobilization: • Age>60yr • Advanced disease and/or bone marrow involvement • Previous radiation therapy and chemotherapy • Multiple chemotherapy cycles • Previous treatment with melphalan, carmustine, or fludarabine.

  3. Failure Rates (cell count<2x10^6 CD34+ cells/kg) for First Mobilizers after 5 Apheresis Days* *Pusic I, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008; 14(9):1045-1056

  4. Suboptimal mobilization can lead to: • Inability to undergo aHSCT • Increased costs to the healthcare system • Loss of quality of life • Increased number of days of apheresis • Delayed, partial, or failed stem-cell engraftment • Increased need for blood transfusions • Elevated rates of MDS* *Kalaycio M, et al. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol. 2006; 24(22):3640-3610

  5. Plerixafor (AMD3100; Mozobil) • A bicyclam molecule • Reversible inhibitor of SDF-1a/CXCR4 binding • Initially developed as an inhibitor of HIV entry into CD4+ cells • Caused rapid, transient leukocytosis in patients with HIV infection and healthy volunteers, stimulating interest in capacity to mobilize CD34+ cells • Very water soluble • Low molecular weight (MW = 502)

  6. Mozobil Mechanism of Action of Mozobil • Mozobil blocks the CXCR4-SDF-1a interaction, releasing stem cells from bone marrow into the circulating blood • no growth factor • release within hours • synergistic with G-CSF

  7. Clinical efficacy • The efficacy and safety of Mozobil was evaluated in 2 randomized, double-blind, placebo-controlled, multicenter phase 3 studied (AMD 3100-3101-NHL, AMD 3100-3102-MM)

  8. Phase 3 TrialsFDA granted SPA Dec 2004 - Primary Efficacy Endpoint 150 NHL G-CSF + MOZOBIL Primary Endpoint: > 5 million CD34+ cells/kg in 4 or fewer days of apheresis 3101: 300 NHL Patients 20% difference 150 NHL G-CSF + placebo 150 MM G-CSF + MOZOBIL Primary Endpoint: > 6 million CD34+ cells/kg in 2 or fewer days of apheresis 3102: 300 MM Patients 20% difference 150 MM G-CSF + placebo

  9. Efficacy - CD34+ Cell Mobilization in NHL Patients

  10. Secondary Efficacy: Number of Days to PMN and PLT Engraftment - ITT Note: Includes randomized patients receiving study drug and receiving a transplant. * p-value from Log-Rank test

  11. Efficacy – CD34+ Cell Mobilization in MM Patients

  12. Secondary Efficacy: Number of Days to PMN and PLT Engraftment - ITT Note: Includes randomized patients receiving study drug and receiving a transplant. * p-value from Log-Rank test stratified by baseline PLT (<200,000 dL, > 200,000 dL)

  13. Indications and usage • Mozobil, a hematopoietic stem cell mobilizer, is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma and multiple myeloma

  14. Dosage and administration • Initiate Mozobil treatment after the patient has received G-CSF once daily for 4 days • Repeat Mozobil dose up to 4 consecutive days • Select dose based on 0.24 mg/kg actual body weight • Administer by subcutaneous injection approximately 11 hours prior to initiation of apheresis • Renal impairment: If creatinine clearance is  50 mL/min, decrease dose by one-third to 0.16 mg/kg

  15. Daily dose of G-CSF Apheresis session Mozobil dosing Stem Cell Mobilization Protocol Mobilization Collection Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8

  16. Clinical Adverse Reactions • The most common AEs (>10%) reported by Mozobil clinical program regardless of cause were: diarrhea, nausea, fatigue, injection site reactions, headache, arthralgia, dizziness, and vomiting. • AEs less than 5% but were reported to be related to Mozobil during HSC mobilization and apheresis include: abdominal pain, hyperhidrosis, abdominal distention, dry mouth, erythema, stomach discomfort, malaise, oral hypoaesthesia, constipation, dyspepsia, and musculoskeletal pain. • Mild to moderate systemic AEs (less than 1%) include: urticaria, periorbital edema, dyspnea, or hypoxia. • Less than 1% experiencedvasovagal reactions, orthostatic hypotension, and/or syncope following SC injections- appropriate precautions should be taken.

  17. HSC Mobilization Using Mozobil in Israel • Mozobil is FDA approved in the USA and in the European Union. • In Israel Mozobil is used through Genzyme Corporation compassionate use protocol (for NHL or MM patients only). • Currently, Mozobil was used for HSC mobilization in only 16 patients from 5 medical centers in Israel.

  18. HSC Mobilization Using Mozobil in Israel (cont) • Overall 16 pts: 9 NHL, 7 MM • All failed previous one or two HSC collections (defined as cell count<2x10^6 CD34+ cells/kg) • At the time of Mozobil mobilization pts were either on CR (1/2) or PR. • One MM pt (plasma cell leukemia with PD) and one NHL pt failed collection. • One MM pt- only one aphersis for HSC back-up (pt is intended for allo-HSCT)

  19. * ** ‡ Results of HSC Collection Using Mozobil *Pt is currently on 2nd day apheresis **Pt with MM (plasma cell leukemia) progressive disease ‡Pt with MM- only one apheresis for back-up (planned for allo-HSCT)

  20. Amount of CD34+ Cells Collected Using Mozobil

  21. Percentages of Pts Succeeded in Mobilizing ≥2x10^6/kg and ≥5x10^6/kg CD34+ HSC* *Pt with plasma cell leukemia with PD- not included

  22. AEs in Israel • No significant AE were noted using Mozobil. • One MM pt died two weeks after HSC mobilization, but death was related to the pt morbid condition. • In two different aphereses from two pts we got thick aggregates in the collection bag- related to high WBC and monocytic counts.

  23. Conclusions • Mozobil is indicated in combination with G-CSF to mobilize HSC to the peripheral blood for collection and subsequent aHSCT in patients with NHL and MM. • So far, 93.3% of our patients previously failed HSC collection, succeeded with Mozobil HSC mobilization. • Results of engraftment after aHSCT using HSC mobilized with Mozobil are pending.

  24. Conclusion (2) • Treatment was well tolerated and no serious adverse events were noted. • This initial experience emphasizes Mozobil as an attractive agent for HSC mobilization and may have particular value in heavily pretreated patients.

  25. Thanks • Dr. Lina Atlas: Apheresis unit, Institute of Hematology, Soroka Medical Center • Dr.Yizhar Hardan: Department of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer • Dr. Moshe Yeshurun: Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center • Dr. Tsila Zuckerman: Department of Hematology & Bone Marrow Transplantation, Rambam medical center • Simcha Samuel, MSc: Hadassah medical center • Yuval Levin and Dr. Ayelet Zamri: Genzyme-ISRAEL

More Related